Treating keratinocyte carcinomas with a combination of imiquimod, 5-fluorouracil, and tretinoin using store-and-forward telemedicine in the age of coronavirus disease 2019 to promote social distancing

The recent coronavirus disease 19 (COVID-19) crisis has resulted in an economic downturn and the implementation of policies such as social distancing and shelter-in-place.1 In light of these events, the US government has passed the Coronavirus Preparedness and Response Supplemental Appropriations Act. This act relaxed Health Insurance Portability and Accountability Act regulations and instituted new avenues of revenue for telehealth, including (1) real-time audio-video technology communication; (2) store-and-forward technology, which collects data to be later transmitted via virtual check-ins, email, or other digital applications; and (3) verbal/audio-only communication without images or prerecorded videos.2 Moreover, latest polls have found that around two-thirds of patients are willing to try telehealth because of the pandemic.3 These factors have allowed physicians to provide virtual care for patients who are receptive to such technology while adhering to newly instituted policies. The various treatment options for keratinocyte carcinomas (KCs)—surgery, radiation, lasers, curettage and electrodesiccation, photodynamic therapy, intralesional chemotherapy, and cryotherapy—require in-person office visits for implementation.4 Currently, effective treatment options for KCs that allow for entirely no in-person visits are unknown or limited. The combination of topical antitumor agents (imiquimod 5% cream [IMI], 5-fluorouracil 2% solution [5-FU], and tretinoin 0.1% cream [TRET]) with limited cryotherapy was found to be efficacious in the treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).5 With the recent institution of social distancing, we evaluated the use of store-and-forward technology with this combination (IMI/5-FU/TRET) for the treatment of KCs that required no in-office patient visits.